Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT7M3PI)

• DTT Name: Ribosomal protein S6 kinase (S6K)
• Synonyms: Ribosomal s6 kinase
• Gene Name: S6K
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Kinase
• UniProt ID: NOUNIPROTAC
• TTD ID: T45597

Molecular Interaction Atlas (MIA) of This DTT

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY-2584702	DML8M3B	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
LY2780301	DM93AJW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
LYS-6KAKT1	DMLXGAI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
XL418	DME0F5W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

1 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27410995-Compound-Figure3k	DMJ0QLB	N. A.	N. A.	Patented	[5]

References

• [1] DOI: 10.1016/S1359-6349(10)71767-5
• [2] A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84.
• [3] A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
• [4] Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
• [5] Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.